Both are also regulated by NFκB (50, 51) and their increased expression is likely due to enhanced NFκB activity as seen early after activation of CLL cells with IL2 and resiquimod in vitro (Figure 3A). Here, NFKB1 is linked to B-cell chronic lymphocytic leukemia.